Jiayao Wang

Dr. Jiayao Wang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2018 in Genome Medicine
Verified
Journal Article
Open access
PDF file
NZNa Zhu
Na Zhu
CWCarrie Welch
Carrie Welch
JWJiayao Wang
Jiayao Wang
PAPhilip M. Allen
Philip M. Allen
CGClaudia Gonzaga-Jauregui
Claudia Gonzaga-Jauregui
WCWendy K. Chung
Wendy K. Chung
Pulmonary arterial hypertension (PAH) is a rare disease characterized by distinctive changes in pulmonary arterioles that lead to progressive pulmonary arterial pressures, right-sided heart failure, and a high mortality rate. Up to 30% of adult and 75% of pediatric PAH cases are associated with congenital heart disease (PAH-CHD), and the underlying etiology is largely unknown. There are no known major risk genes for PAH-CHD. To identify novel genetic causes of PAH-CHD, we performed whole exome sequencing in 256 PAH-CHD patients. We performed a case-control gene-based association test of rare deleterious variants using 7509 gnomAD whole genome sequencing population controls. We then screened a separate cohort of 413 idiopathic and familial PAH patients without CHD for rare deleterious variants in the top association gene. We identified SOX17 as a novel candidate risk gene (p = 5.5e−7). SOX17 is highly constrained and encodes a transcription factor involved in Wnt/β-catenin and Notch signaling during development. We estimate that rare deleterious variants contribute to approximately 3.2% of PAH-CHD cases. The coding variants identified include likely gene-disrupting (LGD) and deleterious missense, with most of the missense variants occurring in a highly conserved HMG-box protein domain. We further observed an enrichment of rare deleterious variants in putative targets of SOX17, many of which are highly expressed in developing heart and pulmonary vasculature. In the cohort of PAH without CHD, rare deleterious variants of SOX17 were observed in 0.7% of cases. These data strongly implicate SOX17 as a new risk gene contributing to PAH-CHD as well as idiopathic/familial PAH. Replication in other PAH cohorts and further characterization of the clinical phenotype will be important to confirm the precise role of SOX17 and better estimate the contribution of genes regulated by SOX17.

14 November 2019 in Genome Medicine
Verified
Journal Article
Open access
PDF file
NZNa Zhu
Na Zhu
MPMichael W. Pauciulo
Michael W. Pauciulo
CWCarrie L. Welch
Carrie L. Welch
KLKatie A. Lutz
Katie A. Lutz
ACAnna W. Coleman
Anna W. Coleman
WNWilliam C. Nichols
William C. Nichols
Background: Group 1 pulmonary arterial hypertension (PAH) is a rare disease with high mortality despite recent therapeutic advances. Pathogenic remodeling of pulmonary arterioles leads to increased pulmonary pressures, right ventricular hypertrophy, and heart failure. Mutations in bone morphogenetic protein receptor type 2 and other risk genes predispose to disease, but the vast majority of non-familial cases remain genetically undefined.Methods: To identify new risk genes, we performed exome sequencing in a large cohort from the National Biological Sample and Data Repository for PAH (PAH Biobank,n = 2572). We then carried out rare deleterious variant identification followed by case-control gene-based association analyses. To control for population structure, only unrelated European cases (n = 1832) and controls (n = 12,771) were used in association tests. Empiricalpvalues were determined by permutation analyses, and the threshold for significance defined by Bonferroni’s correction for multiple testing.Results: Tissue kallikrein 1 (KLK1) and gamma glutamyl carboxylase (GGCX) were identified as new candidate risk genes for idiopathic PAH (IPAH) with genome-wide significance. We note that variant carriers had later mean age of onset and relatively moderate disease phenotypes compared to bone morphogenetic receptor type 2 variant carriers. We also confirmed the genome-wide association of recently reported growth differentiation factor (GDF2) with IPAH and further implicate T-box 4 (TBX4) with child-onset PAH.Conclusions: We report robust association of novel genesKLK1andGGCXwith IPAH, accounting for ~ 0.4% and 0.9% of PAH Biobank cases, respectively. Both genes play important roles in vascular hemodynamics and inflammation but have not been implicated in PAH previously. These data suggest new genes, pathogenic mechanisms, and therapeutic targets for this lethal vasculopathy.

1 February 2019 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MGMythily Ganapathi
Mythily Ganapathi
LPLeah R. Padgett
Leah R. Padgett
KYKentaro Yamada
Kentaro Yamada
ODOrrin Devinsky
Orrin Devinsky
RWRebecca Willaert
Rebecca Willaert
WCWendy K. Chung
Wendy K. Chung

8 July 2020 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
JWJiayao Wang
Jiayao Wang
PAPriyanka R. Ahimaz
Priyanka R. Ahimaz
SHSomaye Hashemifar
Somaye Hashemifar
JKJulie Khlevner
Julie Khlevner
JPJoseph A. Picoraro
Joseph A. Picoraro
WCWendy K. Chung
Wendy K. Chung

4 October 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
ITInna Tabansky
Inna Tabansky
ATAkemi J. Tanaka
Akemi J. Tanaka
JWJiayao Wang
Jiayao Wang
GZGuanglan Zhang
Guanglan Zhang
IDIrena Dujmovic
Irena Dujmovic
JSJoel N. H. Stern
Joel N. H. Stern
Neuromyelitis optica spectrum disorders (NMOSD) are rare, debilitating autoimmune diseases of the central nervous system. Many NMOSD patients have antibodies to Aquaporin-4 (AQP4). Prior studies show associations of NMOSD with individual Human Leukocyte Antigen (HLA) alleles and with mutations in the complement pathway and potassium channels. HLA allele associations with NMOSD are inconsistent between populations, suggesting complex relationships between the identified alleles and risk of disease. We used a retrospective case-control approach to identify contributing genetic variants in patients who met the diagnostic criteria for NMOSD and their unaffected family members. Potentially deleterious variants identified in NMOSD patients were compared to members of their families who do not have the disease and to existing databases of human genetic variation. HLA sequences from patients from Belgrade, Serbia, were compared to the frequency of HLA haplotypes in the general population in Belgrade. We analyzed exome sequencing on 40 NMOSD patients and identified rare inherited variants in the complement pathway and potassium channel genes. Haplotype analysis further detected two haplotypes, HLA-A*01, B*08, DRB1*03 and HLA-A*01, B*08, C*07, DRB1*03, DQB1*02, which were more prevalent in NMOSD patients than in unaffected individuals.In silicomodeling indicates that HLA molecules within these haplotypes are predicted to bind AQP4 at several sites, potentially contributing to the development of autoimmunity. Our results point to possible autoimmune and neurodegenerative mechanisms that cause NMOSD, and can be used to investigate potential NMOSD drug targets.

27 October 2020 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
ACAndrew H. Chiang
Andrew H. Chiang
JCJonathan Chang
Jonathan Chang
JWJiayao Wang
Jiayao Wang
DVDennis Vitkup
Dennis Vitkup